Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 3
2012 1
2013 4
2014 2
2015 2
2016 1
2017 1
2018 3
2019 5
2020 3
2021 11
2022 7
2023 12
2024 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
The Interplay between Glioblastoma and Its Microenvironment.
Dapash M, Hou D, Castro B, Lee-Chang C, Lesniak MS. Dapash M, et al. Among authors: lee chang c. Cells. 2021 Aug 31;10(9):2257. doi: 10.3390/cells10092257. Cells. 2021. PMID: 34571905 Free PMC article. Review.
Myeloid cell-derived creatine in the hypoxic niche promotes glioblastoma growth.
Rashidi A, Billingham LK, Zolp A, Chia TY, Silvers C, Katz JL, Park CH, Delay S, Boland L, Geng Y, Markwell SM, Dmello C, Arrieta VA, Zilinger K, Jacob IM, Lopez-Rosas A, Hou D, Castro B, Steffens AM, McCortney K, Walshon JP, Flowers MS, Lin H, Wang H, Zhao J, Sonabend A, Zhang P, Ahmed AU, Brat DJ, Heiland DH, Lee-Chang C, Lesniak MS, Chandel NS, Miska J. Rashidi A, et al. Among authors: lee chang c. Cell Metab. 2024 Jan 2;36(1):62-77.e8. doi: 10.1016/j.cmet.2023.11.013. Epub 2023 Dec 21. Cell Metab. 2024. PMID: 38134929
STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma.
Zhang P, Rashidi A, Zhao J, Silvers C, Wang H, Castro B, Ellingwood A, Han Y, Lopez-Rosas A, Zannikou M, Dmello C, Levine R, Xiao T, Cordero A, Sonabend AM, Balyasnikova IV, Lee-Chang C, Miska J, Lesniak MS. Zhang P, et al. Among authors: lee chang c. Nat Commun. 2023 Mar 23;14(1):1610. doi: 10.1038/s41467-023-37328-9. Nat Commun. 2023. PMID: 36959214 Free PMC article.
New Approaches to Glioblastoma.
Khasraw M, Fujita Y, Lee-Chang C, Balyasnikova IV, Najem H, Heimberger AB. Khasraw M, et al. Among authors: lee chang c. Annu Rev Med. 2022 Jan 27;73:279-292. doi: 10.1146/annurev-med-042420-102102. Epub 2021 Oct 19. Annu Rev Med. 2022. PMID: 34665646 Free PMC article. Review.
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
Fares J, Ahmed AU, Ulasov IV, Sonabend AM, Miska J, Lee-Chang C, Balyasnikova IV, Chandler JP, Portnow J, Tate MC, Kumthekar P, Lukas RV, Grimm SA, Adams AK, Hébert CD, Strong TV, Amidei C, Arrieta VA, Zannikou M, Horbinski C, Zhang H, Burdett KB, Curiel DT, Sachdev S, Aboody KS, Stupp R, Lesniak MS. Fares J, et al. Among authors: lee chang c. Lancet Oncol. 2021 Aug;22(8):1103-1114. doi: 10.1016/S1470-2045(21)00245-X. Epub 2021 Jun 29. Lancet Oncol. 2021. PMID: 34214495 Free PMC article. Clinical Trial.
IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.
Zannikou M, Duffy JT, Levine RN, Seblani M, Liu Q, Presser A, Arrieta VA, Chen CJ, Sonabend AM, Horbinski CM, Lee-Chang C, Miska J, Lesniak MS, Gottschalk S, Balyasnikova IV. Zannikou M, et al. Among authors: lee chang c. J Immunother Cancer. 2023 Feb;11(2):e006239. doi: 10.1136/jitc-2022-006239. J Immunother Cancer. 2023. PMID: 36759014 Free PMC article.
Next Steps for Immunotherapy in Glioblastoma.
Cao TQ, Wainwright DA, Lee-Chang C, Miska J, Sonabend AM, Heimberger AB, Lukas RV. Cao TQ, et al. Among authors: lee chang c. Cancers (Basel). 2022 Aug 20;14(16):4023. doi: 10.3390/cancers14164023. Cancers (Basel). 2022. PMID: 36011015 Free PMC article. Review.
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.
Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C, Shilati J, Jaishankar D, Chen L, Gould A, Zhang D, Yuan J, Zhao W, Ling X, Burks JK, Laffleur B, Amidei C, Bruce JN, Lukas RV, Yamaguchi JT, Cieremans D, Rothschild G, Basu U, McCord M, Brat DJ, Zhang H, Cooper LAD, Zhang B, Sims P, Cloughesy TF, Prins R, Canoll P, Stupp R, Heimberger AB, Horbinski C, Iwamoto FM, Rabadan R, Sonabend AM. Arrieta VA, et al. Among authors: lee chang c. Nat Cancer. 2021 Dec;2(12):1372-1386. doi: 10.1038/s43018-021-00260-2. Epub 2021 Nov 29. Nat Cancer. 2021. PMID: 35121903 Free PMC article.
Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade.
Dmello C, Zhao J, Chen L, Gould A, Castro B, Arrieta VA, Zhang DY, Kim KS, Kanojia D, Zhang P, Miska J, Yeeravalli R, Habashy K, Saganty R, Kang SJ, Fares J, Liu C, Dunn G, Bartom E, Schipma MJ, Hsu PD, Alghamri MS, Lesniak MS, Heimberger AB, Rabadan R, Lee-Chang C, Sonabend AM. Dmello C, et al. Among authors: lee chang c. Nat Commun. 2023 Mar 22;14(1):1566. doi: 10.1038/s41467-023-36878-2. Nat Commun. 2023. PMID: 36949040 Free PMC article.
60 results